Blood glucose readings over time, with superimposed LOESS trend lines.

Slides:

Advertisements

Similar presentations

Follow Up Questions Diabetes is caused by an increase in blood glucose. People with diabetes II also have a very high risk for developing Alzheimer’s disease.

Advertisements

Toujeo® and it’s Place in Therapy

Diabetes and Hypertension Health Screening in the Fresno Sikh Population: A Cross Sectional Approach Baljit Singh Dhesi 1,2 1University of California,

Mean rates of insulin and glucagon delivery from an artificial pancreas at various blood glucose levels. The device was programmed to establish and maintain.

Components of a CGM record over a 3

Volume 70, Issue 8, Pages (October 2006)

Rank-order bar chart of percentage of patient-days with blood glucose results > 299 mg/dl for non-ICU units. Rank-order bar chart of percentage of patient-days.

George Dailey, MD Mayo Clinic Proceedings

Summary of DURATION development program select efficacy results: absolute difference in change in A1C, body weight, systolic blood pressure, and LDL cholesterol.

Fig. 1. Glycemic variability in three hypothetical patients who have the same mean blood glucose concentration. Patient B has relatively small variations.

Depicted are patient and disease factors used to determine optimal A1C targets. Depicted are patient and disease factors used to determine optimal A1C.

The means and SDs of the data from all Glucommander runs from 1984 to 1998 are graphed. The means and SDs of the data from all Glucommander runs from 1984.

Impact of U-100 RHI administered with V-Go at OV1 (3 months after initiation) and OV2 (6 months after initiation) (n = 11) at 3 months (P = 0.32) and at.

C. Fabrizio, A. Procopio Clinical Microbiology and Infection

The worldwide association between mean annual temperature and age-adjusted, sex-adjusted, income-adjusted and obesity-adjusted prevalence of raised fasting.

Reasons patients were excluded from the switch from atorvastatin to simvastatin J. A. Usher-Smith, et al. Int J Clin Pract 2007; 61:15–23.

Respondents’ perceptions on (A) the potential of IDegLira compared with basal-bolus therapy to improve patient motivation to reach their target blood glucose.

Subgroup analysis. Subgroup analysis. Effect of vitamin D supplementation on outcome variables in subgroups defined by baseline levels of the respective.

(A–C) Time-course changes in morning time fasted, and daytime (A) IL-6, (B) TNF-α, and (C) β-hydroxybutyrate concentrations. (A–C) Time-course changes.

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

Scatterplot showing the association between baseline weight and weight change at 1 year, relative to baseline for each treatment group. Scatterplot showing.

Effects of Pay-for-Performance on the Quality of Primary Care in England Mean Scores for Clinical Quality at the Practice Level for Aspects of Care for.

Change in (A) total cholesterol; (B) LDL-cholesterol; (C) HDL-cholesterol and (D) triglycerides over 5 years in response to 12-week intensive lifestyle.

The proportion of patients confronted with a cardiovascular risk factor (CVRF) they were previously unaware of, referring to the instrument based tests.

Change in %A1C over 5 years in response to 12-week intensive lifestyle intervention used in a real-world clinical practice. Change in %A1C over 5 years.

Change in (A) systolic blood pressure and (B) diastolic blood pressure over 5 years in response to 12-week intensive lifestyle intervention in a real-world.

When queried about the supply of endocrinologists to manage diabetes, respondents felt that there are not enough endocrinologists. When queried about the.

Serial measurements of serum glucose, anion gap, serum carbon dioxide, and serum triglycerides throughout the patient's hospital stay. Serial measurements.

The development of plasma (p-)C-peptide responses to an intravenous glucose (0.5 g glucose/kg body wt) and glucagon (1 mg) infusion test up to 5–7 years.

Involvement of IRS-1 in L-783,281–stimulated increases in [Ca2+]i and exocytosis. Involvement of IRS-1 in L-783,281–stimulated increases in [Ca2+]i and.

Mean (95% CI) fasting s-glucose at baseline and 6-month, 12-month, and 24-month follow-up, overall and by sex (A), and by baseline age (B), education (C),

Percentage of patients with type 2 diabetes with A1C < 7% (n = 248), blood pressure > 130/80 mmHg (n = 248), and LDL cholesterol < 100 mg/dl (n = 207)

Flow chart of patients who met inclusion/exclusion criteria in the identified study population.1 Excluded because they were living in nursing facility.

Percentage of Florida adults with diagnosed diabetes who received services or engaged in self-management practices by DSME duration category, Florida BRFSS.

Mean ± SEM concentration of insulin in plasma and CSF and glucose in plasma 30 min after the intraperitoneal administration of DET or NPH insulin at different.

Percentage of patients who had their pre-evening capillary blood glucose monitored at least once during their steroid therapy. Percentage of patients who.

Pooled risk with 95% CI of ACM (A) and CVD risk (B) for the highest vs

Plasma levels of GLP-1 are increased in patients with critical illness and correlate with disease severity. Plasma levels of GLP-1 are increased in patients.

Diabetes intervention (ACM) and control (TTR-only) care package details. ACM = additional case management. BP = blood pressure. FBG = fasting blood glucose.

Effects of in vivo AICAR treatment on blood glucose and lactate concentrations. Effects of in vivo AICAR treatment on blood glucose and lactate concentrations.

The possible off-target effect of increased heart failure hospitalizations from saxagliptin in the SAVOR trial. The possible off-target effect of increased.

Effect of 4 weeks of an intensive exercise program on vaspin serum concentrations in normal glucose tolerant (NGT) individuals and patients with IGT or.

Odor-induced brain responses in patients with type 2 diabetes (A) and normal control subjects (B) (with AlphaSim correction, voxel level: P < 0.001, cluster.

Percentage of weight loss over 5 years in response to 12-week intensive lifestyle intervention in a real-world clinical practice. Percentage of weight.

GTTs and ITTs. A: GTTs of WT (◇), LepTg (♦), Akita (open circles), and LepTg:Akita (closed circles) mice at 8 and 16 weeks of age. GTTs and ITTs. A: GTTs.

Blood glucose levels in chicken embryos.

Proportion of patients experiencing documented symptomatic hypoglycemia (blood glucose

Metabolic parameters in the three groups of patients during l-arginine infusion. Metabolic parameters in the three groups of patients during l-arginine.

Kaplan-Meier survival analysis for all-cause and CVD mortality in 2,823 type 2 diabetic patients stratified by CKD according to each creatinine-based equation.

Number of antihypertensive agents prescribed for known nephropaths in phases I and II (▪), with blood pressure recordings falling outside guidelines, compared.

(A) Mean glucose concentrations (standard error) over a 3-hour period in 21 placebo- and 15 pramlintide-treated patients with type 1 diabetes treated for.

Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.

Comparison of blood glucose within and between probiotic and control groups at the three time points. Comparison of blood glucose within and between probiotic.

Noncontrast computed tomography of patient C. B

Correlation between serum visfatin concentrations and the clinical stage (A) and tumor size (B, C) of HCCs. A and B, the correlations were determined by.

Distribution of daily frequency of BGM

The continuous line represents the sensor glucose values.

Initiation and adjustment of insulin regimens.

Trends in age-adjusted diagnosed diabetes prevalence and incidence among adults aged 18–79 years, 1980–2017. Trends in age-adjusted diagnosed diabetes.

Postoperative blood glucose levels and total insulin requirement.

Association of overall survival and PAP-specific (A, B) and PA2024-specific (C, D) CTL activity at week 26 using categorical (tertile) analysis and continuous.

Control chart demonstrating percent of patients up to date on PPSV23 out of total number of eligible clinic patients. Control chart demonstrating percent.

Elevated blood glucose vs time.

Glucose log of a 51-year-old patient with insulin-requiring type 2 diabetes and an A1C of 7.8% who takes 10 mg of glyburide at bedtime and 25 units of.

Based on personal experience, conversations with experts, and a literature review, this is a partial list of factors that can affect blood glucose. Based.

(A) Twenty-four-hour plasma profiles of insulin and amylin in healthy subjects. (A) Twenty-four-hour plasma profiles of insulin and amylin in healthy subjects.

A: Glucose levels during basal-bolus and SSI treatment.

Receiver operator characteristic (ROC) curve for fasting blood glucose (FBG) predicting posttransplantation diabetes (PTD) using time 0 FBG (a) and screening.

ERRs (degludec/glargine U100) of hypoglycemia in Hispanic and non-Hispanic patients during the SWITCH 2 trial. ERRs (degludec/glargine U100) of hypoglycemia.

Benchmarking scatterplot for non-ICU units.

Presentation transcript:

Blood glucose readings over time, with superimposed LOESS trend lines. Blood glucose readings over time, with superimposed LOESS trend lines. Data came from a pilot project of a telehealth intervention connecting nurse case managers to Medicaid patients with diabetes served by a multispecialty clinic in the Pacific Northwest. A) All patients enrolled in the pilot project. B) Overall average blood glucose for this patient improved over time, and variability in blood glucose decreased over time. Both of these are indicators of better disease control. C) There was no change in average blood glucose variability over time for this patient. D) This patient initially was not deeply engaged in the program; once complete patient engagement occurred, blood glucose control improved. Marit L. Bovbjerg et al. Clin Diabetes 2017;35:227-231 ©2017 by American Diabetes Association